Hyperglycemia and glycation in diabetic complications

Antioxidants and Redox Signaling

Volumn 11, Issue 12, 2009, Pages 3071-3109

  Negre Salvayre, Anne ^a   Salvayre, Robert ^a,b   Augé, Nathalie ^a   Pamplona, Reinald ^c   Portero Otín, Manuel ^c  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c UNIVERSITY OF LLEIDA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; BILIRUBIN; BILIVERDIN; CAPTOPRIL; CARBON MONOXIDE; CATALASE; GLITAZONE DERIVATIVE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; GLYOXALASE; HEME OXYGENASE; HEMOGLOBIN; INSULIN; LIPOPROTEIN; MEGLITINIDE; METHYLGLYOXAL; PROBUCOL; REACTIVE OXYGEN METABOLITE; SCLEROPROTEIN; SERUM ALBUMIN; SULFONYLUREA; SUPEROXIDE DISMUTASE; THIOREDOXIN; URIC ACID; VITAMIN;

ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; APOPTOSIS; ARTERIAL STIFFNESS; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; CARCINOGENESIS; CELL MATURATION; CELL METABOLISM; CELLULAR STRESS RESPONSE; CROSS LINKING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DNA POLYMORPHISM; ENDOTHELIAL DYSFUNCTION; ENVIRONMENTAL FACTOR; ENZYME MECHANISM; EXTRACELLULAR MATRIX; FOAM CELL; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GLUCOSE METABOLISM; GLYCATION; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; KIDNEY METABOLISM; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; LIVER METABOLISM; MICROANGIOPATHY; MITOGENESIS; MOLECULAR DYNAMICS; NONHUMAN; OSTEOPOROSIS; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RESTENOSIS; REVIEW; RNA SPLICING; SIGNAL TRANSDUCTION; THROMBOCYTE FUNCTION; THROMBOGENESIS; TISSUE INJURY; URINARY EXCRETION; WOUND HEALING IMPAIRMENT;

BLOOD GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; OXIDATIVE STRESS;

EID: 70449449612     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2484     Document Type: Review

References (368)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998.
3. Abdel-Wahab YH, O'Harte FP, Ratcliff H, McClenaghan NH, Barnett CR, and Flatt PR. Glycation of insulin in the islets of Langerhans of normal and diabetic animals. Diabetes 45: 1489-1496, 1996.
4. Abraham NG and Kappas A. Heme oxygenase and the cardiovascular-renal system. Free Radic Biol Med 39: 1-25, 2005.
5. Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, and Thornalley PJ. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48: 1590-1603, 2005.
6. Ahmed N and Thornalley PJ. Advanced glycation end-products: what is their relevance to diabetic complications? Diabetes Obes Metab 9: 233-245, 2007.
7. Ahmed N, Thornalley PJ, Luthen R, Haussinger D, Sebe-kova K, Schinzel R, Voelker W, and Heidland A. Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. J Hepatol 41: 913-919, 2004.
8. Aldini G, Dalle-Donne I, Facino RM, Milzani A, and Carini M. Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med Res Rev 27: 817-868, 2007.
9. Aleshin A, Ananthakrishnan R, Li Q, Rosario R, Lu Y, Qu W, Song F, Bakr S, Szabolcs M, D'Agati V, Liu R, Homma S, Schmidt AM, Yan SF, and Ramasamy R. RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. Am J Physiol Heart Circ Physiol 294: H1823-H1832, 2008.
10. Alikhani M, Maclellan CM, Raptis M, Vora S, Trackman PC, and Graves DT. Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor. Am J Physiol Cell Physiol 292: C850-C856, 2007.
11. Amore A, Cirina P, Conti G, Cerutti F, Bagheri N, Emancipator SN, and Coppo R. Amadori-configurated albumin induces nitric oxide-dependent apoptosis of endothelial cells: a possible mechanism of diabetic vasculopathy. Ne-phrol Dial Transplant 19: 53-60, 2004.
12. Anderson MM, Requena JR, Crowley JR, Thorpe SR, and Heinecke JW. The myeloperoxidase system of human phagocytes generates N-epsilon-(carboxymethyl) lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104: 103-113, 1999.
13. Artwohl M, Graier WF, Roden M, Bischof M, Freudenthaler A, Waldhausl W, and Baumgartner-Parzer SM. Diabetic LDL triggers apoptosis in vascular endothelial cells. Diabetes 52: 1240-1247, 2003.
14. Avery NC and Bailey AJ. The effects of the Maillard reaction on the physical properties and cell interactions of collagen. Pathol Biol (Paris) 54: 387-395, 2006.
15. Baranano DE, Rao M, Ferris CD, and Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A 99: 16093-16098, 2002.
16. Bartling B, Demling N, Silber RE, and Simm A. Pro-liferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation end-products. Am J Respir Cell Mol Biol 34: 83-91, 2006.
17. Baynes JW. From life to death: the struggle between chemistry and biology during aging: the Maillard reaction as an amplifier of genomic damage. Biogerontology 1: 235-246, 2000.
18. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412, 1991.
19. Baynes JW, Watkins NG, Fisher CI, Hull CJ, Patrick JS, Ahmed MU, Dunn JA, and Thorpe SR. The Amadori product on protein: structure and reactions. Prog Clin Biol Res 304: 43-67, 1989.
20. Bellmunt MJ, Portero M, Pamplona R, Cosso L, Odetti P, and Prat J. Evidence for the Maillard reaction in rat lung collagen and its relationship with solubility and age. Bio-chim Biophys Acta 1272: 53-60, 1995.
21. Beltramo E, Pomero F, Allione A, D'Alu F, Ponte E, and Porta M. Pericyte adhesion is impaired on extracellular matrix produced by endothelial cells in high hexose concentrations. Diabetologia 45: 416-419, 2002.
22. Berlanga J, Cibrian D, Guillen I, Freyre F, Alba JS, Lopez-Saura P, Merino N, Aldama A, Quintela AM, Triana ME, Montequin JF, Ajamieh H, Urquiza D, Ahmed N, and Thor-nalley PJ. Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. Clin Sci (Lond) 109: 83-95, 2005.
23. Berndt C, Lillig CH, and Holmgren A. Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. Am J Physiol Heart Circ Physiol 292: H1227-H1236, 2007.
24. Bhattacharyya N, Pal A, Patra S, Haldar AK, Roy S, and Ray M. Activation of macrophages and lymphocytes by methylglyoxal against tumor cells in the host. Int Im-munopharmacol 8: 1503-1512, 2008.
25. Bortolotto LA. [Modifications of structural and functional properties of large arteries in diabetes mellitus]. Arq Bras Endocrinol Metabol 51: 176-184, 2007.
26. Boulanger E, Wautier MP, Gane P, Mariette C, Devuyst O, and Wautier JL. The triggering of human peritoneal me-sothelial cell apoptosis and oncosis by glucose and gly-coxydation products. Nephrol Dial Transplant 19: 2208-2216, 2004.
27. Brand MD, Affourtit C, Esteves TC, Green K, Lambert AJ, Miwa S, Pakay JL, and Parker N. Mitochondrial superox-ide: production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med 37: 755-767, 2004.
28. Brand MD, Pamplona R, Portero-Otin M, Requena JR, Roebuck SJ, Buckingham JA, Clapham JC, and Cadenas S. Oxidative damage and phospholipid fatty acyl composition in skeletal muscle mitochondria from mice under-expressing or overexpressing uncoupling protein 3. Biochem J 368: 597-603, 2002.
29. Brizzi MF, Dentelli P, Gambino R, Cabodi S, Cassader M, Castelli A, Defilippi P, Pegoraro L, and Pagano G. STAT5 activation induced by diabetic LDL depends on LDL gly-cation and occurs via src kinase activity. Diabetes 51: 3311-3317, 2002.
30. Brouard S, Otterbein LE, Anrather J, Tobiasch E, Bach FH, Choi AM, and Soares MP. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med 192: 1015-1026, 2000.
31. Brouwers O, Teerlink T, van Bezu J, Barto R, Stehouwer CD, and Schalkwijk CG. Methylglyoxal and methylglyoxal-arginine adducts do not directly inhibit endothelial nitric oxide synthase. Ann N Y Acad Sci 1126: 231-234, 2008.
32. Brown MS and Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 52: 223-261, 1983.
33. Brown SM, Smith DM, Alt N, Thorpe SR, and Baynes JW. Tissue-specific variation in glycation of proteins in diabetes: evidence for a functional role of amadoriase enzymes. Ann N Y Acad Sci 1043: 817-823, 2005.
34. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
35. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625, 2005.
36. Bucciarelli LG, Ananthakrishnan R, Hwang YC, Kaneko M, Song F, Sell DR, Strauch C, Monnier VM, Yan SF, Schmidt AM, and Ramasamy R. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 57: 1941-1951, 2008.
37. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, and Schmidt AM. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106: 2827-2835, 2002.
38. Bunn HF and Higgins PJ. Reaction of monosaccharides with proteins: possible evolutionary significance. Science 213: 222-224, 1981.
39. Burke-Gaffney A, Callister ME, and Nakamura H. Thior-edoxin: friend or foe in human disease? Trends Pharmacol Sci 26: 398-404, 2005.
40. Cai W, He JC, Zhu L, Chen X, Wallenstein S, Striker GE, and Vlassara H. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am J Pathol 170: 1893-1902, 2007.
41. Cai W, He JC, Zhu L, Lu C, and Vlassara H. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci U S A 103: 13801-13806, 2006.
42. Cai W, He JC, Zhu L, Peppa M, Lu C, Uribarri J, and Vlassara H. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 110: 285-291, 2004.
43. Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, Dilley RJ, Cooper ME, and Allen TJ. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106: 246-253, 2002.
44. Cantero AV, Portero-Otin M, Ayala V, Auge N, Sanson M, Elbaz M, Thiers JC, Pamplona R, Salvayre R, and Negre-Salvayre A. Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis. FASEB J 21: 3096-3106, 2007. (Pubitemid 47565530)
45. Cefalu WT, Bell-Farrow AD, Wang ZQ, Sonntag WE, Fu MX, Baynes JW, and Thorpe SR. Caloric restriction decreases age-dependent accumulation of the glycoxidation products, N epsilon-(carboxymethyl)lysine and pentosi-dine, in rat skin collagen. J Gerontol A Biol Sci Med Sci 50: B337-B341, 1995.
46. Ceriello A. Oxidative stress and diabetes-associated complications. Endocr Pract 12(suppl 1): 60-62, 2006.
47. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54: 1-7, 2005.
48. Ceriello A, Bortolotti N, Crescentini A, Motz E, Lizzio S, Russo A, Ezsol Z, Tonutti L, and Taboga C. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur J Clin Invest 28: 329-333, 1998.
49. Ceriello A, Bortolotti N, Motz E, Crescentini A, Lizzio S, Russo A, Tonutti L, and Taboga C. Meal-generated oxida-tive stress in type 2 diabetic patients. Diabetes Care 21: 1529-1533, 1998.
50. Chait A, Brazg RL, Tribble DL, and Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 94: 350-356, 1993.
51. Chakravarthy U, Hayes RG, Stitt AW, McAuley E, and Archer DB. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 47: 945-952, 1998.
52. Chan WH and Wu HJ. Methylglyoxal and high glucose co-treatment induces apoptosis or necrosis in human umbilical vein endothelial cells. J Cell Biochem 103: 1144-1157, 2008.
53. Chan WH, Wu HJ, and Shiao NH. Apoptotic signaling in methylglyoxal- treated human osteoblasts involves oxida-tive stress, c-Jun N-terminal kinase, caspase-3, and p21-activated kinase 2. J Cell Biochem 100: 1056-1069, 2007.
54. Chang PC, Chen TH, Chang CJ, Hou CC, Chan P, and Lee HM. Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. Kidney Int 65: 1664-1675, 2004.
55. Chang T, Wang R, and Wu L. Methylglyoxal-induced nitric oxide and peroxynitrite production in vascular smooth muscle cells. Free Radic Biol Med 38: 286-293, 2005.
56. Charissou A, Ait-Ameur L, and Birlouez-Aragon I. Kinetics of formation of three indicators of the Maillard reaction in model cookies: influence of baking temperature and type of sugar. J Agric Food Chem 55: 4532-4539, 2007.
57. Chen S, Cohen MP, Lautenslager GT, Shearman CW, and Ziyadeh FN. Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells. Kidney Int 59: 673-681, 2001.
58. Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, and Yan SD. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med 7: 735-742, 2007.
59. Chen Y, Akirav EM, Chen W, Henegariu O, Moser B, Desai D, Shen JM, Webster JC, Andrews RC, Mjalli AM, Rothlein R, Schmidt AM, Clynes R, and Herold KC. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol 181: 4272-4278, 2008.
60. Cho HM, Choi SH, Hwang KC, Oh SY, Kim HG, Yoon DH, Choi MA, Lim S, Song H, Jang Y, and Kim TW. The Src/PLC/PKC/MEK/ERK signaling pathway is involved in aortic smooth muscle cell proliferation induced by gly-cated LDL. Mol Cells 19: 60-66, 2005.
61. Choi SW, Benzie IF, Ma SW, Strain JJ, and Hannigan BM. Acute hyperglycemia and oxidative stress: direct cause and effect? Free Radic Biol Med 44: 1217-1231, 2008.
62. Chuang PY, Yu Q, Fang W, Uribarri J, and He JC. Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int 72: 965-976, 2007.
63. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuc-curullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, and Mezzetti A. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108: 1070-1077, 2003.
64. Clark A and Nilsson MR. Islet amyloid: a complication of islet dysfunction or an aetiological factor in type 2 diabetes? Diabetologia 47: 157-169, 2004.
65. Cohen G, Livovsky DM, Kapitulnik J, and Sasson S. Bilir-ubin increases the expression of glucose transporter-1 and the rate of glucose uptake in vascular endothelial cells. Rev Diabet Stud 3: 127-133, 2006.
66. Cohen MP, Hud E, and Wu VY. Amelioration of diabetic nephropathy by treatment with monoclonal antibodies against glycated albumin. Kidney Int 45: 1673-1679, 1994.
67. Cohen MP, Lautenslager GT, Hud E, Shea E, Wang A, Chen S, and Shearman CW. Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency. Am J Physiol Renal Physiol 292: F789-F795, 2007.
68. Cohen MP, Shea E, Chen S, and Shearman CW. Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells. J Lab Clin Med 141: 242-249, 2003.
69. Cohen MP, Wu VY, and Cohen JA. Glycated albumin stimulates fibronectin and collagen IV production by glo-merular endothelial cells under normoglycemic conditions. Biochem Biophys Res Commun 239: 91-94, 1997.
70. Cortizo AM, Sedlinsky C, McCarthy AD, Blanco A, and Schurman L. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol 536: 38-46, 2006.
71. Dattilo BM, Fritz G, Leclerc E, Kooi CW, Heizmann CW, and Chazin WJ. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry 46: 6957-6970, 2007.
72. de Koning EJ, Morris ER, Hofhuis FM, Posthuma G, Hoppener JW, Morris JF, Capel PJ, Clark A, and Verbeek JS. Intra-and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A 91: 8467-8471, 1994.
73. de la Cruz KI, Tsai PI, Cohn WE, and Cooley DA. Re-vascularization treatment recommendations based on atherosclerotic disease distribution: coronary artery bypass grafting versus stenting. Curr Atheroscler Rep 10: 434-437, 2008.
74. De Vriese AS, Tilton RG, Mortier S, and Lameire NH. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant 21: 2549-2555, 2006.
75. Del Corso A, Cappiello M, and Mura U. From a dull enzyme to something else: facts and perspectives regarding aldose reductase. Curr Med Chem 15: 1452-1461, 2008.
76. Delpierre G, Veiga-da-Cunha M, Vertommen D, Buys-schaert M, and Van Schaftingen E. Variability in erythro-cyte fructosamine 3-kinase activity in humans correlates with polymorphisms in the FN3K gene and impacts on haemoglobin glycation at specific sites. Diabetes Metab 32: 31-39, 2006.
77. Denis U, Lecomte M, Paget C, Ruggiero D, Wiernsperger N, and Lagarde M. Advanced glycation end-products induce apoptosis of bovine retinal pericytes in culture: involvement of diacylglycerol/ceramide production and oxidative stress induction. Free Radic Biol Med 33: 236-247, 2002.
78. Desfaits AC, Serri O, and Renier G. Gliclazide reduces the induction of human monocyte adhesion to endothelial cells by glycated albumin. Diabetes Obes Metab 1: 113-120, 1999.
79. Di Loreto S, Zimmitti V, Sebastiani P, Cervelli C, Falone S, and Amicarelli F. Methylglyoxal causes strong weakening of detoxifying capacity and apoptotic cell death in rat hippocampal neurons. Int J Biochem Cell Biol 40: 245-257, 2008.
80. Ding Q and Keller JN. Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain. Neurosci Lett 373: 67-72, 2005.
81. Ding Y, Kantarci A, Hasturk H, Trackman PC, Malabanan A, and Van Dyke TE. Activation of RAGE induces elevated O2~ generation by mononuclear phagocytes in diabetes. J Leukoc Biol 81: 520-527, 2007.
82. Dong Y, Wu Y, Wu M, Wang S, Zhang J, Xie Z, Xu J, Song P, Wilson K, Zhao Z, Lyons T, and Zou MH. Activation of protease calpain by oxidized and glycated LDL: increases the degradation of endothelial nitric oxide synthase. J Cell Mol Med 2008. Postprint; 10.1111/j.1582-4934.2008.00416.
83. Du J, Zeng J, Ou X, Ren X, and Cai S. Methylglyoxal downregulates Raf-1 protein through a ubiquitination-mediated mechanism. Int J Biochem Cell Biol 38: 1084-1091, 2006.
84. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, and Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112: 1049-1057, 2003.
85. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, and Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108: 1341-1348, 2001.
86. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, and Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 97: 12222-12226, 2000.
87. Dunn JA, Patrick JS, Thorpe SR, and Baynes JW. Oxidation of glycated proteins: age-dependent accumulation of N epsilon-(carboxymethyl)lysine in lens proteins. Biochemistry 28: 9464-9468, 1989.
88. Duraisamy Y, Slevin M, Smith N, Bailey J, Zweit J, Smith C, Ahmed N, and Gaffney J. Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: possible relevance to wound healing in diabetes. Angiogenesis 4: 277-288, 2001.
89. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, and Baynes JW. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91: 2463-2469, 1993.
90. Elgawish A, Glomb M, Friedlander M, and Monnier VM. Involvement of hydrogen peroxide in collagen cross-linking by high glucose in vitro and in vivo. J Biol Chem 271: 12964-12971, 1996.
91. Engerman RL, Kern TS, and Larson ME. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs. Diabetologia 37: 141-144, 1994.
92. Esposito K, Marfella R, and Giugliano D. Stress hyperglycemia, inflammation, and cardiovascular events. Diabetes Care 26: 1650-1651, 2003.
93. Faist V and Erbersdobler HF. Metabolic transit and in vivo effects of melanoidins and precursor compounds deriving from the Maillard reaction. Ann Nutr Metab 45: 1-12, 2001.
94. Falcone C, Campo I, Emanuele E, Buzzi MP, Zorzetto M, Sbarsi I, and Cuccia M. Relationship between the-374T/A RAGE gene polymorphism and angiographic coronary artery disease. Int J Mol Med 14: 1061-1064, 2004.
95. Faure P, Polge C, Monneret D, Favier A, and Halimi S. Plasma 15-F2t isoprostane concentrations are increased during acute fructose loading in type 2 diabetes. Diabetes Metab 34: 148-154, 2008.
96. Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, and Curatola G. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 38: 163-169, 2001.
97. Ferretti G, Rabini RA, Bacchetti T, Vignini A, Salvolini E, Ravaglia F, Curatola G, and Mazzanti L. Glycated low density lipoproteins modify platelet properties: a compositional and functional study. J Clin Endocrinol Metab 87: 2180-2184, 2002.
98. Fleming T, Rabbani N, and Thornalley PJ. Preparation of nucleotide advanced glycation endproducts: imidazopur-inone adducts formed by glycation of deoxyguanosine with glyoxal and methylglyoxal. Ann N Y Acad Sci 1126: 280-282, 2008.
99. Florczyk UM, Jozkowicz A, and Dulak J. Biliverdin re-ductase: new features of an old enzyme and its potential therapeutic significance. Pharmacol Rep 60: 38-48, 2008.
100. Forbes JM, Coughlan MT, and Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57: 1446-1454, 2008.
101. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, and Allen TJ. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53: 1813-1823, 2004.
102. Forster A, Kuhne Y, and Henle T. Studies on absorption and elimination of dietary Maillard reaction products. Ann N Y Acad Sci 1043: 474-481, 2005.
103. Forstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 5: 338-349, 2008.
104. Fountain WC, Requena JR, Jenkins AJ, Lyons TJ, Smyth B, Baynes JW, and Thorpe SR. Quantification of N-(glucitol)ethanolamine and N-(carboxymethyl) serine: two products of nonenzymatic modification of aminopho-spholipids formed in vivo. Anal Biochem 272: 48-55, 1999.
105. Fowler SP, Williams K, Resendez RG, Hunt KJ, Hazuda HP, and Stern MP. Fueling the obesity epidemic? artificially sweetened beverage use and long-term weight gain. Obesity (Silver Spring) 16: 1894-1900, 2008.
106. Franke S, Siggelkow H, Wolf G, and Hein G. Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem 113: 154-161, 2007.
107. Friedlander MA and Hricik DE. Optimizing end-stage renal disease therapy for the patient with diabetes mellitus. Semin Nephrol 17: 331-345, 1997.
108. Friedlander MA, Wu YC, Elgawish A, and Monnier VM. Early and advanced glycosylation end products: kinetics of formation and clearance in peritoneal dialysis. J Clin Invest 97: 728-735, 1996.
109. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, and Thorpe SR. The advanced glycation end product, N-epsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271: 9982-9986, 1996.
110. Fukami K, Yamagishi S, Ueda S, and Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des 14: 946-952, 2008.
111. Fukui M, Tanaka M, Shiraishi E, Harusato I, Hosoda H, Asano M, Hasegawa G, and Nakamura N. Relationship between serum bilirubin and albuminuria in patients with type 2 diabetes. Kidney Int 74: 1197-1201, 2008.
112. Fukunaga M, Miyata S, Higo S, Hamada Y, Ueyama S, and Kasuga M. Methylglyoxal induces apoptosis through oxi-dative stress-mediated activation of p38 mitogen-activated protein kinase in rat Schwann cells. Ann N Y Acad Sci 1043: 151-157, 2005.
113. Gabbay KH, Merola LO, and Field RA. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes. Science 151: 209-210, 1966.
114. Galle J, Schneider R, Winner B, Lehmann-Bodem C, Schinzel R, Munch G, Conzelmann E, and Wanner C. Glyc-oxidized LDL impair endothelial function more potently than oxidized LDL: role of enhanced oxidative stress. Atherosclerosis 138: 65-77, 1998.
115. Gangoiti MV, Cortizo AM, Arnol V, Felice JI, and McCarthy AD. Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells. Eur J Pharmacol 600: 140-147, 2008.
116. Giannini S, Serio M, and Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 27: 982-991, 2004.
117. Goh KC, Lim YP, Ong SH, Siak CB, Cao X, Tan YH, and Guy GR. Identification of p90, a prominent tyrosine-phosphorylated protein in fibroblast growth factor-stimulated cells, as 80K-H. J Biol Chem 271: 5832-5838, 1996.
118. Goh SY and Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 93: 1143-1152, 2008.
119. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899, 2003.
120. Goldin A, Beckman JA, Schmidt AM, and Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114: 597-605, 2006.
121. Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, Nowygrod S, Wolf BM, Caliste X, Yan SF, Stern DM, and Schmidt AM. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 159: 513-525, 2001.
122. Graves DT, Liu R, Alikhani M, Al-Mashat H, and Trackman PC. Diabetes-enhanced inflammation and apoptosis: impact on periodontal pathology. J Dent Res 85: 15-21, 2006.
123. Grune T, Jung T, Merker K, and Davies KJ. Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and ''aggresomes'' during oxi-dative stress, aging, and disease. Int J Biochem Cell Biol 36: 2519-2530, 2004.
124. Ha H and Lee HB. Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int Suppl 77: S19-S25, 2000.
125. Hansen B, Longati P, Elvevold K, Nedredal GI, Schled-zewski K, Olsen R, Falkowski M, Kzhyshkowska J, Carls-son F, Johansson S, Smedsrod B, Goerdt S, Johansson S, and McCourt P. Stabilin-1 and stabilin-2 are both directed into the early endocytic pathway in hepatic sinusoidal endo-thelium via interactions with clathrin/AP-2, independent of ligand binding. Exp Cell Res 303: 160-173, 2005.
126. Hansen B, Svistounov D, Olsen R, Nagai R, Horiuchi S, and Smedsrod B. Advanced glycation end products impair the scavenger function of rat hepatic sinusoidal endothelial cells. Diabetologia 45: 1379-1388, 2002.
127. Haslbeck KM, Bierhaus A, Erwin S, Kirchner A, Nawroth P, Schlotzer U, Neundorfer B, and Heuss D. Receptor for advanced glycation endproduct (RAGE)-mediated nuclear factor-kappaB activation in vasculitic neuropathy. Muscle Nerve 29: 853-860, 2004.
128. Hayase F, Nagaraj RH, Miyata S, Njoroge FG, and Monnier VM. Aging of proteins: immunological detection of a glucose-derived pyrrole formed during Maillard reaction in vivo. J Biol Chem 264: 3758-3764, 1989.
129. Hayden MR and Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab (Lond) 1: 10, 2004.
130. Heidland A, Sebekova K, and Schinzel R. Advanced gly-cation end products and the progressive course of renal disease. Am J Kidney Dis 38: S100-S106, 2001. (Pubitemid 32927622)
131. Heizmann CW, Ackermann GE, and Galichet A. Pathologies involving the S100 proteins and RAGE. Subcell Biochem 45: 93-138, 2007.
132. Herold K, Moser B, Chen Y, Zeng S, Yan SF, Ramasamy R, Emond J, Clynes R, and Schmidt AM. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J Leukoc Biol 82: 204-212, 2007.
133. Higai K, Shimamura A, and Matsumoto K. Amadori-modified glycated albumin predominantly induces E-selectin expression on human umbilical vein endothelial cells through NADPH oxidase activation. Clin Chim Acta 367: 137-143, 2006.
134. Hipkiss AR. Glycation, ageing and carnosine: are carnivorous diets beneficial? Mech Ageing Dev 126: 1034-1039, 2005.
135. Hoang A, Murphy AJ, Coughlan MT, Thomas MC, Forbes JM, O'Brien R, Cooper ME, Chin-Dusting JP, and Sviridov D. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 50: 1770-1779, 2007.
136. Hodgkinson CP, Laxton RC, Patel K, and Ye S. Advanced glycation end-product of low density lipoprotein activates the Toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol 28: 2275-2281, 2008.
137. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, and Schmidt AM. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97: 889-901, 1999.
138. Hofmann SM, Dong HJ, Li Z, Cai W, Altomonte J, Thung SN, Zeng F, Fisher EA, and Vlassara H. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 51: 2082-2089, 2002.
139. Horiuchi S, Sakamoto Y, and Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids 25: 283-292, 2003.
140. Huang WJ, Tung CW, Ho C, Yang JT, Chen ML, Chang PJ, Lee PH, Lin CL, and Wang JY. Ras activation modulates methylglyoxal-induced mesangial cell apoptosis through superoxide production. Ren Fail 29: 911-921, 2007.
141. Hudson BI, Stickland MH, Futers TS, and Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcrip-tional regulation and their association with diabetic reti-nopathy. Diabetes 50: 1505-1511, 2001.
142. Hudson BI, Stickland MH, and Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes 47: 1155-1157, 1998.
143. Hudson BI, Wendt T, Bucciarelli LG, Rong LL, Naka Y, Yan SF, and Schmidt AM. Diabetic vascular disease: it's all the RAGE. Antioxid Redox Signal 7: 1588-1600, 2005.
144. Huijberts MS, Schaper NC, and Schalkwijk CG. Advanced glycation end products and diabetic foot disease. Diabetes Metab Res Rev 24(suppl 1): S19-S24, 2008.
145. Hulbert AJ, Pamplona R, Buffenstein R, and Buttemer WA. Life and death: metabolic rate, membrane composition, and life span of animals. Physiol Rev 87: 1175-1213, 2007.
146. Iacobini C, Amadio L, Oddi G, Ricci C, Barsotti P, Missori S, Sorcini M, Di Mario U, Pricci F, and Pugliese G. Role of galectin-3 in diabetic nephropathy. J Am Soc Nephrol 14: S264-S270, 2003.
147. Ichikawa K, Yoshinari M, Iwase M, Wakisaka M, Doi Y, Iino K, Yamamoto M, and Fujishima M. Advanced glyco-sylation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients. Atherosclerosis 136: 281-287, 1998.
148. Imanaga Y, Sakata N, Takebayashi S, Matsunaga A, Sasaki J, Arakawa K, Nagai R, Horiuchi S, Itabe H, and Takano T. In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. Atherosclerosis 150: 343-355, 2000.
149. Isoda K, Folco E, Marwali MR, Ohsuzu F, and Libby P. Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis. Atherosclerosis 198: 307-312, 2008.
150. Isono M, Cruz MC, Chen S, Hong SW, and Ziyadeh FN. Extracellular signal-regulated kinase mediates stimulation of TGF-beta1 and matrix by high glucose in mesangial cells. J Am Soc Nephrol 11: 2222-2230, 2000.
151. Iwashima Y, Eto M, Hata A, Kaku K, Horiuchi S, Ushikubi F, and Sano H.
152. Jia X, Olson DJ, Ross AR, and Wu L. Structural and functional changes in human insulin induced by methylglyoxal. FASEB J 20: 1555-1557, 2006.
153. Jono T, Miyazaki A, Nagai R, Sawamura T, Kitamura T, and Horiuchi S. Lectin-like oxidized low density lipopro-tein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett 511: 170-174, 2002.
154. Jono T, Nagai R, Lin X, Ahmed N, Thornalley PJ, Takeya M, and Horiuchi S. N-epsilon-(carboxymethyl)lysine and 3-DG-imidazolone are major AGE structures in protein modification by 3-deoxyglucosone. J Biochem 136: 351-358, 2004.
155. Kalapos MP. The tandem of free radicals and methyl-glyoxal. Chem Biol Interact 171: 251-271, 2008.
156. Kallner A. Elimination of 14C-glycated albumin from serum of rabbit. Scand J Clin Lab Invest 50: 763-768, 1990.
157. Kani S, Nakayama E, Yoda A, Onishi N, Sougawa N, Hazaka Y, Umeda T, Takeda K, Ichijo H, Hamada Y, and Minami Y. Chk2 kinase is required for methylglyoxal-induced G2/M cell-cycle checkpoint arrest: implication of cell-cycle checkpoint regulation in diabetic oxidative stress signaling. Genes Cells 12: 919-928, 2007.
158. Kankova K, Marova I, Zahejsky J, Muzik J, Stejskalova A, Znojil V, and Vacha J. Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. Metabolism 50: 1152-1160, 2001.
159. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, and Yamasaki Y. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diabetes Vasc Dis Res 5: 190-197, 2008.
160. Kedziora-Kornatowska KZ, Luciak M, Blaszczyk J, and Pawlak W. Lipid peroxidation and activities of antioxidant enzymes in erythrocytes of patients with non-insulin dependent diabetes with or without diabetic nephropathy. Nephrol Dial Transplant 13: 2829-2832, 1998.
161. Kikuchi G, Yoshida T, and Noguchi M. Heme oxygenase and heme degradation. Biochem Biophys Res Commun 338: 558-567, 2005.
162. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, and Schmidt AM. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274: 31740-31749, 1999.
163. Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ Jr, Taguchi A, Olson K, Bucciarelli L, Goova M, Hofmann MA, Cataldegirmen G, D'Agati V, Pischetsrieder M, Stern DM, and Schmidt AM. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 21: 905-910, 2001.
164. Kleindienst A, Hesse F, Bullock MR, and Buchfelder M. The neurotrophic protein S100B: value as a marker of brain damage and possible therapeutic implications. Prog Brain Res 161: 317-325, 2007.
165. Kobayashi T, Oku H, Komori A, Okuno T, Kojima S, Obayashi H, Sugiyama T, Hasegawa G, Fukui M, Naka-mura N, and Ikeda T. Advanced glycation end products induce death of retinal neurons via activation of nitric oxide synthase. Exp Eye Res 81: 647-654, 2005.
166. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, and Harris HE. RAGE is the major receptor for the proin-flammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61: 1-9, 2005.
167. Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, and Schleicher ED. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest 101: 160-169, 1998.
168. Kontush A and Chapman MJ. Why is HDL functionally deficient in type 2 diabetes? Curr Diabetes Rep 8: 51-59, 2008.
169. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, and Vlassara H. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94: 6474-6479, 1997.
170. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, and King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prosta-noids in the glomeruli of diabetic rats. J Clin Invest 100: 115-126, 1997.
171. Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 5(suppl 1): S19-S27, 2003.
172. Kuzuya M, Satake S, Ai S, Asai T, Kanda S, Ramos MA, Miura H, Ueda M, and Iguchi A. Inhibition of angiogenesis on glycated collagen lattices. Diabetologia 41: 491-499, 1998.
173. Laga M, Cottyn A, Van Herreweghe F, Vanden Berghe W, Haegeman G, Van Oostveldt P, Vandekerckhove J, and Vancompernolle K. Methylglyoxal suppresses TNF-alpha-induced NF-kappaB activation by inhibiting NF-kappaB DNA-binding. Biochem Pharmacol 74: 579-589, 2007.
174. Lajemi M, Gautier S, and Benetos A. [Rigidity of large arteries and cardiovascular risk. epidemiological aspects and genetic determinants]. Pathol Biol (Paris) 47: 614-622, 1999.
175. Lam MC, Tan KC, and Lam KS. Glycoxidized low-density lipoprotein regulates the expression of scavenger receptors in THP-1 macrophages. Atherosclerosis 177: 313-320, 2004.
176. Lapshina EA, Sudnikovich EJ, Maksimchik JZ, Zab-rodskaya SV, Zavodnik LB, Kubyshin VL, Nocun M, Kaz-mierczak P, Dobaczewski M, Watala C, and Zavodnik IB. Antioxidative enzyme and glutathione S-transferase activities in diabetic rats exposed to long-term ASA treatment. Life Sci 79: 1804-1811, 2006.
177. Lee AY and Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 13: 23-30, 1999.
178. Lee MY and Griendling KK. Redox signaling, vascular function, and hypertension. Antioxid Redox Signal 10: 1045-1059, 2008.
179. Lemkadem B, Loiseau D, Larcher G, Malthiery Y, and Foussard F. Effect of the nonenzymatic glycosylation of high density lipoprotein-3 on the cholesterol ester transfer protein activity. Lipids 34: 1281-1286, 1999.
180. Levi Z, Shaish A, Yacov N, Levkovitz H, Trestman S, Gerber Y, Cohen H, Dvir A, Rhachmani R, Ravid M, and Harats D. Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. Diabetes Obes Metab 5: 45-50, 2003.
181. Lewis P, Stefanovic N, Pete J, Calkin AC, Giunti S, Thallas-Bonke V, Jandeleit-Dahm KA, Allen TJ, Kola I, Cooper ME, and de Haan JB. Lack of the antioxidant enzyme glutathi-one peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation 115: 2178-2187, 2007.
182. Li D, Devaraj S, Fuller C, Bucala R, and Jialal I. Effect of alpha-tocopherol on LDL oxidation and glycation: in vitro and in vivo studies. J Lipid Res 37: 1978-1986, 1996.
183. Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, Truong LD, Johnson RJ, and Lan HY. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 18: 176-178, 2004.
184. Li L and Renier G. Activation of nicotinamide adenine di-nucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression. Metabolism 55: 1516-1523, 2006.
185. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Grone HJ, Kurschus FC, Schmidt AM, Yan SD, Martin E, Schleicher E, Stern DM, Hammer-ling GG, Nawroth PP, and Arnold B. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 113: 1641-1650, 2004. (Pubitemid 39071688)
186. Lillig CH and Holmgren A. Thioredoxin and related molecules: from biology to health and disease. Antioxid Redox Signal 9: 25-47, 2007.
187. Lin L. RAGE on the Toll Road? Cell Mol Immunol 3: 351-358, 2006.
188. Liu XP, Pang YJ, Zhu WW, Zhao TT, Zheng M, Wang YB, Sun ZJ, and Sun SJ. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways. Clin Exp Pharmacol Physiol 36: 287-296, 2009.
189. Logsdon CD, Fuentes MK, Huang EH, and Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 7: 777-789, 2007.
190. Lorenzi M, Montisano DF, Toledo S, and Wong HC. Increased single strand breaks in DNA of lymphocytes from diabetic subjects. J Clin Invest 79: 653-656, 1987.
191. Lu C, He JC, Cai W, Liu H, Zhu L, and Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci U S A 101: 11767-11772, 2004.
192. Lyons TJ, Silvestri G, Dunn JA, Dyer DG, and Baynes JW. Role of glycation in modification of lens crystallins in diabetic and nondiabetic senile cataracts. Diabetes 40: 1010-1015, 1991.
193. Ma SW, Tomlinson B, and Benzie IF. A study of the effect of oral glucose loading on plasma oxidant:antioxidant balance in normal subjects. Eur J Nutr 44: 250-254, 2005.
194. Ma Z, Westermark GT, Li ZC, Engstrom U, and Westermark P. Altered immunoreactivity of islet amyloid polypeptide (IAPP) may reflect major modifications of the IAPP molecule in amyloidogenesis. Diabetologia 40: 793-801, 1997.
195. Maillard D. Action des acides aminés sur les sucres: formation des melanoidines par voie methodique. Compt Rend Hebd Seances Acad Sci 154: 66-68, 1912.
196. Mamo JC, Szeto L, and Steiner G. Glycation of very low density lipoprotein from rat plasma impairs its catabolism. Diabetologia 33: 339-345, 1990.
197. Mandl-Weber S, Cohen CD, Haslinger B, Kretzler M, and Sitter T. Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int 61: 570-578, 2002.
198. Marfella R, Quagliaro L, Nappo F, Ceriello A, and Giu-gliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 108: 635-636, 2001.
199. Maritim AC, Sanders RA, and Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 17: 24-38, 2003.
200. Mastorikou M, Mackness B, Liu Y, and Mackness M. Gly-cation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabetes Med 25: 1049-1055, 2008.
201. Matsui T, Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, and Inoue H. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 35: 482-489, 2007.
202. Matsunaga-Irie S, Maruyama T, Yamamoto Y, Motohashi Y, Hirose H, Shimada A, Murata M, and Saruta T. Relation between development of nephropathy and the p22phox C242T and receptor for advanced glycation end product G1704T gene polymorphisms in type 2 diabetic patients. Diabetes Care 27: 303-307, 2004.
203. Matsunaga T, Iguchi K, Nakajima T, Koyama I, Miyazaki T, Inoue I, Kawai S, Katayama S, Hirano K, Hokari S, and Komoda T. Glycated high-density lipoprotein induces ap-optosis of endothelial cells via a mitochondrial dysfunction. Biochem Biophys Res Commun 287: 714-720, 2001.
204. McClain DA. Hexosamines as mediators of nutrient sensing and regulation in diabetes. J Diabetes Complications 16: 72-80, 2002.
205. McClung JP, Roneker CA, Mu W, Lisk DJ, Langlais P, Liu F, and Lei XG. Development of insulin resistance and obesity in mice overexpressing cellular glutathione perox-idase. Proc Natl Acad Sci U S A 101: 8852-8857, 2004.
206. McLellan AC, Thornalley PJ, Benn J, and Sonksen PH. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci (Lond) 87: 21-29, 1994.
207. Meli M, Perier C, Ferron C, Parssegny F, Denis C, Gonthier R, Laurent B, Reynaud E, Frey J, and Chamson A. Serum pentosidine as an indicator of Alzheimer's disease. J Alz-heimers Dis 4: 93-96, 2002.
208. Mercer N, Ahmed H, Etcheverry SB, Vasta GR, and Cortizo AM. Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells. Mol Cell Biochem 306: 87-94, 2007.
209. Mercer N, Ahmed H, McCarthy AD, Etcheverry SB, Vasta GR, and Cortizo AM. AGE-R3/galectin-3 expression in osteoblast-like cells: regulation by AGEs. Mol Cell Biochem 266: 17-24, 2004.
210. Min C, Kang E, Yu SH, Shinn SH, and Kim YS. Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells. Diabetes Res Clin Pract 46: 197-202, 1999.
211. Miyazaki Y, Kawano H, Yoshida T, Miyamoto S, Hoka-maki J, Nagayoshi Y, Yamabe H, Nakamura H, Yodoi J, and Ogawa H. Pancreatic B-cell function is altered by oxi-dative stress induced by acute hyperglycaemia. Diabetes Med 24: 154-160, 2007.
212. Miyoshi H, Taguchi T, Sugiura M, Takeuchi M, Yanagisa-wa K, Watanabe Y, Miwa I, Makita Z, and Koike T. Aminoguanidine pyridoxal adduct is superior to amino-guanidine for preventing diabetic nephropathy in mice. Horm Metab Res 34: 371-377, 2002.
213. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, and Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hy-perglycemia in patients with type 2 diabetes. JAMA 295: 1681-1687, 2006.
214. Monnier VM. Intervention against the Maillard reaction in vivo. Arch Biochem Biophys 419: 1-15, 2003.
215. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, and Genuth S. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications: DCCT Skin Collagen Ancillary Study Group: Diabetes Control and Complications Trial. Diabetes 48: 870-880, 1999.
216. Monnier VM and Cerami A. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 211: 491-493, 1981.
217. Monnier VM, Sell DR, Nagaraj RH, Miyata S, Grandhee S, Odetti P, and Ibrahim SA. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 41(suppl 2): 36-41, 1992.
218. Monnier VM and Wu X. Enzymatic deglycation with amadoriase enzymes from Aspergillus sp. as a potential strategy against the complications of diabetes and aging. Biochem Soc Trans 31: 1349-1353, 2003.
219. Moreno JA, Sanchez-Nino MD, Sanz AB, Lassila M, Hol-thofer H, Blanco-Colio LM, Egido J, Ruiz-Ortega M, and Ortiz A. A slit in podocyte death. Curr Med Chem 15: 1645-1654, 2008.
220. Mori Y, Kosaki A, Kishimoto N, Kimura T, Iida K, Fukui M, Nakajima F, Nagahara M, Urakami M, Iwasaka T, and Matsubara H. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Ne-phrol 29: 18-24, 2009.
221. Myers DE, Huang WN, and Larkins RG. Lipoprotein-induced prostacyclin production in endothelial cells and effects of lipoprotein modification. Am J Physiol 271: C1504-C1511, 1996.
222. Nagaraj RH, Kern TS, Sell DR, Fogarty J, Engerman RL, and Monnier VM. Evidence of a glycemic threshold for the formation of pentosidine in diabetic dog lens but not in collagen. Diabetes 45: 587-594, 1996.
223. Nagaraj RH and Sady C. The presence of a glucose-derived Maillard reaction product in the human lens. FEBS Lett 382: 234-238, 1996. (Pubitemid 26092198)
224. Nagaraj RH, Sell DR, Prabhakaram M, Ortwerth BJ, and Monnier VM. High correlation between pentosidine protein crosslinks and pigmentation implicates ascorbate oxidation in human lens senescence and cataractogenesis. Proc Natl Acad Sci U S A 88: 10257-10261, 1991.
225. Naka Y, Bucciarelli LG, Wendt T, Lee LK, Rong LL, Rama-samy R, Yan SF, and Schmidt AM. RAGE axis: Animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol 24: 1342-1349, 2004.
226. Nakajou K, Horiuchi S, Sakai M, Hirata K, Tanaka M, Takeya M, Kai T, and Otagiri M. CD36 is not involved in scavenger receptor-mediated endocytic uptake of glycolaldehyde-and methylglyoxal-modified proteins by liver endothelial cells. J Biochem 137: 607-616, 2005.
227. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, and Imaizumi T. Serum levels of sRAGE, the soluble form of receptor for advanced glyca-tion end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 13: 185-189, 2007. (Pubitemid 46944961)
228. Nakamura S, Li H, Adijiang A, Pischetsrieder M, and Niwa T. Pyridoxal phosphate prevents progression of diabetic nephropathy. Nephrol Dial Transplant 22: 2165-2174, 2007.
229. Nakayama H, Makita Z, Kato M, Taneda S, Yoshida H, YanagisawaK,and Nakagawa S.Quantitative enzyme-linked immunosorbent assay (ELISA) for non-enzymatically gly-cated serum protein. J Immunol Methods 99: 95-100, 1987.
230. Nakayama H, Taneda S, Manda N, Aoki S, Komori K, Kuroda Y, Misawa K, Tsushima S, and Nakagawa S. Radioimmunoassay for nonenzymatically glycated protein in human serum. Clin Chim Acta 158: 293-299, 1986.
231. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, and Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267: 14998-15004, 1992.
232. Negre-Salvayre A, Hirtz C, Carrera G, Cazenave R, Troly M, Salvayre R, Penicaud L, and Casteilla L. A role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation. FASEB J 11: 809-815, 1997.
233. Nicholson AC, Frieda S, Pearce A, and Silverstein RL. Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines: evidence implicating the lipid moiety of the lipoprotein as the binding site. Arterioscler Thromb Vasc Biol 15: 269-275, 1995.
234. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, and Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hy-perglycaemic damage. Nature 404: 787-790, 2000.
235. Nishizawa Y and Koyama H. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease. J Ren Nutr 18: 76-82, 2008.
236. Nitti M, d'Abramo C, Traverso N, Verzola D, Garibotto G, Poggi A, Odetti P, Cottalasso D, Marinari UM, Pronzato MA, and Domenicotti C. Central role of PKCdelta in glycoxidation-dependent apoptosis of human neurons. Free Radic Biol Med 38: 846-856, 2005.
237. Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Januszewski AS, Jenkins AJ, Barter PJ, and Rye KA. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyl-transferase. Diabetologia 50: 643-653, 2007.
238. O'Harte FP, Hojrup P, Barnett CR, and Flatt PR. Identification of the site of glycation of human insulin. Peptides 17: 1323-1330, 1996.
239. Odetti P, Fogarty J, Sell DR, and Monnier VM. Chromato-graphic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 41: 153-159, 1992.
240. Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, and Sugimoto T. The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res 39: 871-875, 2007.
241. Ohgami N, Miyazaki A, Sakai M, Kuniyasu A, Nakayama H, and Horiuchi S. Advanced glycation end products (AGE) inhibit scavenger receptor class B type I-mediated reverse cholesterol transport: a new crossroad of AGE to cholesterol metabolism. J Atheroscler Thromb 10: 1-6, 2003.
242. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, and Makita Z. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 16: 1928-1930, 2002.
243. Okouchi M, Okayama N, and Aw TY. Hyperglycemia potentiates carbonyl stress-induced apoptosis in naive PC-12 cells: relationship to cellular redox and activator protease factor-1 expression. Curr Neurovasc Res 2: 375-386, 2005.
244. Omori K, Ohira T, Uchida Y, Ayilavarapu S, Batista EL Jr, Yagi M, Iwata T, Liu H, Hasturk H, Kantarci A, and Van Dyke TE. Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase. J Leukoc Biol 84: 292-301, 2008.
245. Pamplona R and Barja G. Highly resistant macromolecular components and low rate of generation of endogenous damage: two key traits of longevity. Ageing Res Rev 6: 189-210, 2007.
246. Pamplona R, Bellmunt MJ, Portero M, Riba D, and Prat J. Chromatographic evidence for Amadori product formation in rat liver aminophospholipids. Life Sci 57: 873-879, 1995.
247. Pamplona R, Portero-Otin M, Bellmun MJ, Gredilla R, and Barja G. Aging increases N-epsilon-(carboxymethyl)lysine and caloric restriction decreases N-epsilon-(carboxyethyl) lysine and N-epsilon-(malondialdehyde)lysine in rat heart mitochondrial proteins. Free Radic Res 36: 47-54, 2002.
248. Pamplona R, Portero-Otin M, Requena J, Gredilla R, and Barja G. Oxidative, glycoxidative and lipoxidative damage to rat heart mitochondrial proteins is lower after 4 months of caloric restriction than in age-matched controls. Mech Ageing Dev 123: 1437-1446, 2002.
249. Pamplona R, Portero-Otin M, Ruiz C, Gredilla R, Herrero A, and Barja G. Double bond content of phospholipids and lipid peroxidation negatively correlate with maximum longevity in the heart of mammals. Mech Ageing Dev 112: 169-183, 2000.
250. Pamplona R, Requena JR, Portero-Otin M, Prat J, Thorpe SR, and Bellmunt MJ. Carboxymethylated phosphatidyl-ethanolamine in mitochondrial membranes of mammals: evidence for intracellular lipid glycoxidation. Eur J Biochem 255: 685-689, 1998.
251. Park SH, Marso SP, Zhou Z, Foroudi F, Topol EJ, and Lincoff AM. Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation 104: 815-819, 2001.
252. Passarelli M, Tang C, McDonald TO, O'Brien KD, Gerrity RG, Heinecke JW, and Oram JF. Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes 54: 2198-2205, 2005.
253. Patschan S and Goligorsky MS. Autophagy: the missing link between non-enzymatically glycated proteins inducing apoptosis and premature senescence of endothelial cells? Autophagy 4: 521-523, 2008.
254. Paul RG and Bailey AJ. The effect of advanced glycation end-product formation upon cell-matrix interactions. Int J Biochem Cell Biol 31: 653-660, 1999.
255. Peppa M, Brem H, Ehrlich P, Zhang JG, Cai W, Li Z, Croitoru A, Thung S, and Vlassara H. Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 52: 2805-2813, 2003.
256. Persegol L, Foissac M, Lagrost L, Athias A, Gambert P, Verges B, and Duvillard L. HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 50: 2384-2387, 2007.
257. Peterson SJ, Drummond G, Hyun Kim D, Li M, Positano V, Vanella L, Piccolomini F, Rodella LF, Gastaldelli A, Kusmic C, L'Abbate A, Kappas A, and Abraham NG. Apo A-1 mimetic peptide, L-4F prevents insulin resistance through increased HO-1 and pAMPK in obese mice. J Lipid Res 2009 (in press).
258. Peterson SJ, Drummond G, Kim DH, Li M, Kruger AL, Ikehara S, and Abraham NG. L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J Lipid Res 49: 1658-1669, 2008.
259. Peyroux J and Sternberg M. Advanced glycation end-products (AGEs): pharmacological inhibition in diabetes. Pathol Biol (Paris) 54: 405-419, 2006.
260. Portero-Otin M, Nagaraj RH, and Monnier VM. Chroma-tographic evidence for pyrraline formation during protein glycation in vitro and in vivo. Biochim Biophys Acta 1247: 74-80, 1995.
261. Portero-Otin M, Pamplona R, Bellmunt MJ, Bergua M, Nagaraj RH, and Prat J. Urinary pyrraline as a biochemical marker of non-oxidative Maillard reactions in vivo. Life Sci 60: 279-287, 1997.
262. Portero-Otin M, Pamplona R, Bellmunt MJ, Ruiz MC, Prat J, Salvayre R, and Negre-Salvayre A. Advanced glycation end product precursors impair epidermal growth factor receptor signaling. Diabetes 51: 1535-1542, 2002.
263. Portero-OtinM,PamplonaR,Ruiz MC, Cabiscol E,PratJ,and Bellmunt MJ. Diabetes induces an impairment in the pro-teolytic activity against oxidized proteins and a heterogeneous effect in nonenzymatic protein modifications in the cytosol of rat liver and kidney. Diabetes 48: 2215-2220, 1999.
264. Portero-Otin M, Requena JR, Bellmunt MJ, Ayala V, and Pamplona R. Protein nonenzymatic modifications and proteasome activity in skeletal muscle from the shortlived rat and long-lived pigeon. Exp Gerontol 39: 1527-1535, 2004.
265. Posch K, Simecek S, Wascher TC, Jurgens G, Baumgartner-Parzer S, Kostner GM, and Graier WF. Glycated low-density lipoprotein attenuates shear stress-induced nitric oxide synthesis by inhibition of shear stress-activated L-arginine uptake in endothelial cells. Diabetes 48: 1331-1337, 1999.
266. Prat J, Pamplona R, Sorribas A, Martin S, Vinallonga M, and Segura R. Correlation of plasma lipid fractions with colorimetrically determined glycated hemoglobin in a nondiabetic population. Metabolism 38: 1147-1153, 1989.
267. Pricci F, Leto G, Amadio L, Iacobini C, Romeo G, Cordone S, Gradini R, Barsotti P, Liu FT, Di Mario U, and Pugliese G. Role of galectin-3 as a receptor for advanced glycosyl-ation end products. Kidney Int Suppl 77: S31-S39, 2000.
268. PriceCLand Knight SC. Advanced glycation:a novel outlook on atherosclerosis. Curr Pharm Des 13: 3681-3687, 2007.
269. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, and Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endo-thelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52: 2795-2804, 2003.
270. Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M, Hong M, Stier G, Sattler M, Schleicher E, Speiser W, and Nawroth PP. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 49: 1561-1570, 2000.
271. Ramasamy R, Yan SF, and Schmidt AM. Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts. Mol Nutr Food Res 51: 1111-1115, 2007.
272. Rashid G, Benchetrit S, Fishman D, and Bernheim J. Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. Kidney Int 66: 1099-1106, 2004.
273. Rauvala H and Rouhiainen A. RAGE as a receptor of HMGB1 (Amphoterin): roles in health and disease. Curr Mol Med 7: 725-734, 2007.
274. Ravandi A, Kuksis A, and Shaikh NA. Glycated phospha-tidylethanolamine promotes macrophage uptake of low density lipoprotein and accumulation of cholesteryl esters and triacylglycerols. J Biol Chem 274: 16494-16500, 1999.
275. Redondo C, Burke BJ, and Findlay JB. The retinol-binding protein system: a potential paradigm for steroid-binding globulins? Horm Metab Res 38: 269-278, 2006.
276. Reigle KL, Di Lullo G, Turner KR, Last JA, Chervoneva I, Birk DE, Funderburgh JL, Elrod E, Germann MW, Surber C, Sanderson RD, and San Antonio JD. Non-enzymatic gly-cation of type I collagen diminishes collagen-proteoglycan binding and weakens cell adhesion. J Cell Biochem 104: 1684-1698, 2008.
277. Riboulet-Chavey A, Pierron A, Durand I, Murdaca J, Giu-dicelli J, and Van Obberghen E. Methylglyoxal impairs the insulin signaling pathways independently of the formation of intracellular reactive oxygen species. Diabetes 55: 1289-1299, 2006.
278. Robertson R, Zhou H, Zhang T, and Harmon JS. Chronic oxidative stress as a mechanism for glucose toxicity of the beta cell in type 2 diabetes. Cell Biochem Biophys 48: 139-146, 2007.
279. Robertson RP and Harmon JS. Pancreatic islet beta-cell and oxidative stress: the importance of glutathione peroxidase. FEBS Lett 581: 3743-3748, 2007.
280. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI, Brownlee M, Monnier VM, and Weiss MF. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 289: F420-F430, 2005.
281. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM, Schmidt AM, and Naka Y. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 111: 959-972, 2003.
282. Sakurai S, Yonekura H, Yamamoto Y, Watanabe T, Tanaka N, Li H, Rahman AK, Myint KM, Kim CH, and Yamamoto H. The AGE-RAGE system and diabetic nephropathy. J Am Soc Nephrol 14: S259-S263, 2003.
283. Salama I, Malone PS, Mihaimeed F, and Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol 34: 357-364, 2008.
284. Sampson MJ, Gopaul N, Davies IR, Hughes DA, and Carrier MJ. Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care 25: 537-541, 2002.
285. Sano H, Nagai R, Matsumoto K, and Horiuchi S. Receptors for proteins modified by advanced glycation endproducts (AGE): their functional role in atherosclerosis. Mech Ageing Dev 107: 333-346, 1999.
286. Santini E, Lupi R, Baldi S, Madec S, Chimenti D, Ferrannini E, and Solini A. Effects of different LDL particles on inflammatory molecules in human mesangial cells. Diabeto-logia 51: 2117-2125, 2008.
287. Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, and Takeuchi M. TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med 6: 351-358, 2006.
288. Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, and Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimers Dis Other Demen 21: 197-208, 2006.
289. Schmidt AM and Stern DM. Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease. Front Biosci 6: D1151-D1160, 2001.
290. Schmidt AM, Yan SD, Yan SF, and Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498: 99-111, 2000.
291. Schupp N, Schinzel R, Heidland A, and Stopper H. Geno-toxicity of advanced glycation end products: involvement of oxidative stress and of angiotensin II type 1 receptors. Ann N Y Acad Sci 1043: 685-695, 2005.
292. Schupp N, Stopper H, Rutkowski P, Kobras K, Nebel M, Bahner U, Vienken J, and Heidland A. Effect of different hemodialysis regimens on genomic damage in end-stage renal failure. Semin Nephrol 26: 28-32, 2006. (Pubitemid 43075507)
293. Scott JA and King GL. Oxidative stress and antioxidant treatment in diabetes. Ann N Y Acad Sci 1031: 204-213, 2004.
294. Sebekova K, Hofmann T, Boor P, Sebekova K Jr, Ulicna O, Erbersdobler HF, Baynes JW, Thorpe SR, Heidland A, and Somoza V. Renal effects of oral Maillard reaction product load in the form of bread crusts in healthy and subtotally nephrectomized rats. Ann N Y Acad Sci 1043: 482-491, 2005.
295. Sebekova K, Kupcova V, Schinzel R, and Heidland A. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis: amelioration by liver transplantation. J Hepatol 36: 66-71, 2002.
296. Sell DR. Ageing promotes the increase of early glycation Amadori product as assessed by epsilon-N-(2-furoylmethyl)-L-lysine (furosine) levels in rodent skin collagen: the relationship to dietary restriction and glycoxidation. Mech Ageing Dev 95: 81-99, 1997.
297. Sell DR, Lane MA, Johnson WA, Masoro EJ, Mock OB, Reiser KM, Fogarty JF, Cutler RG, Ingram DK, Roth GS, and Monnier VM. Longevity and the genetic determination of collagen glycoxidation kinetics in mammalian senescence. Proc Natl Acad Sci U S A 93: 485-490, 1996.
298. Sell DR and Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix: implication of pentoses in the aging process. J Biol Chem 264: 21597-21602, 1989.
299. Selvaraj N, Bobby Z, and Sridhar MG. Increased glycation of hemoglobin in chronic renal failure: [corrected] potential role of oxidative stress. Arch Med Res 39: 277-284, 2008.
300. Shanmugam N, Kim YS, Lanting L, and Natarajan R. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J Biol Chem 278: 34834-34844, 2003.
301. Sheehan D, Meade G, Foley VM, and Dowd CA. Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily. Biochem J 360: 1-16, 2001.
302. Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, and Brownlee M. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents
303. Shires TK, Tresnak J, Kaminsky M, Herzog SL, and Truc-Pham B. DNA modification in vivo by derivatives of glucose: enhancement by glutathione depletion. FASEB J 4: 3340-3346, 1990.
304. Shiu SW, Tan KC, Wong Y, Leng L, and Bucala R. Glycox-idized LDL increases lectin-like oxidized low density lipo-protein receptor-1 in diabetes mellitus. Atherosclerosis 203: 522-527, 2009. Epub 2008 Jul 23.
305. Sies H. Oxidative stress: from basic research to clinical application. Am J Med 91: 31S-38S, 1991.
306. Sima AV, Stancu CS, and Simionescu M. Vascular endothe-lium in atherosclerosis. Cell Tissue Res 335: 191-203, 2009. Epub 2008 Sep 17.
307. Singh R, Barden A, Mori T, and Beilin L. Advanced glycation end-products: a review. Diabetologia 44: 129-146, 2001.
308. SonokiK, Yoshinari M,IwaseM, Iino K, Ichikawa K,Ohdo S, Higuchi S, and Iida M. Glycoxidized low-density lipoprotein enhances monocyte chemoattractant protein-1 mRNA expression in human umbilical vein endothelial cells: relation to lysophosphatidylcholine contents and inhibition by nitric oxide donor. Metabolism 51: 1135-1142, 2002.
309. Steinbrecher UP and Witztum JL. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 33: 130-134, 1984.
310. Stern DM, Yan SD, Yan SF, and Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 1: 1-15, 2002.
311. Stopper H, Schupp N, Klassen A, Sebekova K, and Heid-land A. Genomic damage in chronic renal failure: potential therapeutic interventions. J Ren Nutr 15: 81-86, 2005.
312. Sugimoto K, Yasujima M, and Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 14: 953-961, 2008.
313. Sun C, Liang C, Ren Y, Zhen Y, He Z, Wang H, Tan H, Pan X, and Wu Z. Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic Res Cardiol 104: 42-49, 2009.
314. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Ta-kashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, and Kodama T. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386: 292-296, 1997.
315. Takahashi M, Kushida K, Kawana K, Ishihara C, Denda M, Inoue T, and Horiuchi K. Quantification of the cross-link pentosidine in serum from normal and uremic subjects. Clin Chem 39: 2162-2165, 1993.
316. Takamiya R, Takahashi M, Myint T, Park YS, Miyazawa N, Endo T, Fujiwara N, Sakiyama H, Misonou Y, Miyamoto Y, Fujii J, and Taniguchi N. Glycation proceeds faster in mutated Cu, Zn-superoxide dismutases related to familial amyotrophic lateral sclerosis. FASEB J 17: 938-940, 2003.
317. Takeuchi M and Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the patho-genesis of Alzheimer's disease. Curr Pharm Des 14: 973-978, 2008.
318. Tames FJ, Mackness MI, Arrol S, Laing I, and Durrington PN. Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis 93: 237-244, 1992.
319. Tamura Y, Adachi H, Osuga J, Ohashi K, Yahagi N, Sekiya M, Okazaki H, Tomita S, Iizuka Y, Shimano H, Nagai R, Kimura S, Tsujimoto M, and Ishibashi S. FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. J Biol Chem 278: 12613-12617, 2003.
320. Tan AL, Forbes JM, and Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 27: 130-143, 2007.
321. Thornalley PJ. Cell activation by glycated proteins: AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-grand) 44: 1013-1023, 1998.
322. Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Rev 1: 287-298, 2005.
323. Thornalley PJ. Protecting the genome: defence against nu-cleotide glycation and emerging role of glyoxalase I over-expression in multidrug resistance in cancer chemotherapy. Biochem Soc Trans 31: 1372-1377, 2003.
324. Thornalley PJ. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems: role in ageing and disease. Drug Metabol Drug Interact 23: 125-150, 2008.
325. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, and Dawnay A. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375: 581-592, 2003.
326. Thorpe SR and Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25: 275-281, 2003.
327. Toth C, Rong LL, Yang C, Martinez J, Song F, Ramji N, Brussee V, Liu W, Durand J, Nguyen MD, Schmidt AM, and Zochodne DW. Receptor for advanced glycation end products (RAGES) and experimental diabetic neuropathy. Diabetes 57: 1002-1017, 2008.
328. Toure F, Zahm JM, Garnotel R, Lambert E, Bonnet N, Schmidt AM, Vitry F, Chanard J, Gillery P, and Rieu P. Receptor for advanced glycation end-products (RAGE) modulates neutrophil adhesion and migration on glycoxi-dated extracellular matrix. Biochem J 416: 255-261, 2008.
329. Tsimikas S and Witztum JL. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation 103: 1930-1932, 2001.
330. Turkseven S, Kruger A, Mingone CJ, Kaminski P, Inaba M, Rodella LF, Ikehara S, Wolin MS, and Abraham NG. Anti-oxidant mechanism ofheme oxygenase-1 involvesanincrease in superoxide dismutase and catalase in experimental diabetes. Am J Physiol Heart Circ Physiol 289: H701-H707, 2005.
331. Uchiyama A, Ohishi T, Takahashi M, Kushida K, Inoue T, Fujie M, and Horiuchi K. Fluorophores from aging human articular cartilage. J Biochem 110: 714-718, 1991.
332. Uribarri J, Stirban A, Sander D, Cai W, Negrean M, Buenting CE, Koschinsky T, and Vlassara H. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 30: 2579-2582, 2007.
333. Valencia JV, Weldon SC, Quinn D, Kiers GH, DeGroot J, TeKoppele JM, and Hughes TE. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal Biochem 324: 68-78, 2004.
334. Veiga da-Cunha M, Jacquemin P, Delpierre G, Godfraind C, Theate I, Vertommen D, Clotman F, Lemaigre F, De-vuyst O, and Van Schaftingen E. Increased protein glyca-tion in fructosamine 3-kinase-deficient mice. Biochem J 399: 257-264, 2006.
335. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, and Rayfield EJ. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 99: 15596-15601, 2002.
336. Vlassara H, Fuh H, Donnelly T, and Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1: 447-456, 1995.
337. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, and Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A 89: 12043-12047, 1992.
338. Wang R, Kudo M, Yokoyama M, and Asano G. Roles of advanced glycation endproducts (AGE) and receptor for AGE on vascular smooth muscle cell growth. J Nippon Med Sch 68: 472-481, 2001.
339. Wang R, Wang Z, Wu L, Hanna ST, and Peterson-Wake-man R. Reduced vasorelaxant effect of carbon monoxide in diabetes and the underlying mechanisms. Diabetes 50: 166-174, 2001.
340. Wang Y, Vom Hagen F, Pfister F, Bierhaus A, Feng Y, Gans R, and Hammes HP. Receptor for advanced glycation end product expression in experimental diabetic retinopathy. Ann N Y Acad Sci 1126: 42-45, 2008.
341. Wautier JL and Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 27: 535-542, 2001.
342. Wautier JL and Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 95: 233-238, 2004.
343. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, and Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280: E685-E694, 2001.
344. Wu VY, Shearman CW, and Cohen MP. Identification of calnexin as a binding protein for Amadori-modified glycated albumin. Biochem Biophys Res Commun 284: 602-606, 2001.
345. Xanthis A, Hatzitolios A, Koliakos G, and Tatola V. Advanced glycosylation end products and nutrition: a possible relation with diabetic atherosclerosis and how to prevent it. J Food Sci 72: R125-R129, 2007.
346. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, and King GL. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 43: 1122-1129, 1994.
347. Xu B, Ji Y, Yao K, Cao YX, and Ferro A. Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Clin Sci (Lond) 109: 439-446, 2005.
348. Yamagishi S, Matsui T, Nakamura K, Takeuchi M, and Inoue H. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Protein Pept Lett 15: 850-853, 2008.
349. Yamagishi S, Nakamura K, and Inoue H. Possible participation of advanced glycation end products in the patho-genesis of osteoporosis in diabetic patients. Med Hypotheses 65: 1013-1015, 2005. (Pubitemid 41425882)
350. Yamagishi S, Ueda S, Matsui T, Nakamura K, and Okuda S. Role of advanced glycation end products (AGEs) and oxi-dative stress in diabetic retinopathy. Curr Pharm Des 14: 962-968, 2008.
351. Yamagishi S, Yonekura H, Yamamoto Y, Katsuno K, Sato F, Mita I, Ooka H, Satozawa N, Kawakami T, Nomura M, and Yamamoto H. Advanced glycation end products-driven angiogenesis in vitro: induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 272: 8723-8730, 1997.
352. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M, and Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 276: 25096-25100, 2001.
353. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, and Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108: 261-268, 2001.
354. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, and Kindy M. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 6: 643-651, 2000.
355. Yan SF, Ramasamy R, Bucciarelli LG, Wendt T, Lee LK, Hudson BI, Stern DM, Lalla E, S DUY, Rong LL, Naka Y, and Schmidt AM. RAGE and its ligands: a lasting memory in diabetic complications? Diab Vasc Dis Res 1: 10-20, 2004.
356. Yan SF, Ramasamy R, Naka Y, and Schmidt AM. Glyca-tion, inflammation, and RAGE: a scaffold for the macro-vascular complications of diabetes and beyond. Circ Res 93: 1159-1169, 2003.
357. Yan SF, Ramasamy R, and Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 4: 285-293, 2008.
358. Yao D, Taguchi T, Matsumura T, Pestell R, Edelstein D, Giardino I, Suske G, Rabbani N, Thornalley PJ, Sarthy VP, Hammes HP, and Brownlee M. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem 282: 31038-31045, 2007.
359. Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, Juhasz O, Crow MT, Tilton RG, and Denner L. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50: 1495-1504, 2001.
360. Younis N, Sharma R, Soran H, Charlton-Menys V, Else-weidy M, and Durrington PN. Glycation as an atherogenic modification of LDL. Curr Opin Lipidol 19: 378-384, 2008.
361. Zamora R, Grishin A, Wong C, Boyle P, Wang J, Hackam D, Upperman JS, Tracey KJ, and Ford HR. High-mobility group box 1 protein is an inflammatory mediator in nec-rotizing enterocolitis: protective effect of the macrophage deactivator semapimod. Am J Physiol Gastrointest Liver Physiol 289: G643-G652, 2005.
362. Zhao R and Shen GX. Functional modulation of antioxidant enzymes in vascular endothelial cells by glycated LDL. Atherosclerosis 179: 277-284, 2005.
363. Zhao R and Shen GX. Involvement of heat shock factor-1 in glycated LDL-induced upregulation of plasminogen activator inhibitor-1 in vascular endothelial cells. Diabetes 56: 1436-1444, 2007.
364. Zhou Z, Han JY, Xi CX, Xie JX, Feng X, Wang CY, Mei L, and Xiong WC. HMGB1 regulates RANKL-induced osteo-clastogenesis in a manner dependent on RAGE. J Bone Miner Res 23: 1084-1096, 2008.
365. Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Forudi F, Zhou X, Qu W, Lu Y, Stern DM, Schmidt AM, Lincoff AM, and Topol EJ. Receptor for AGE (RAGE) mediates neoin-timal formation in response to arterial injury. Circulation 107: 2238-2243, 2003.
366. Zhu W, Sano H, Nagai R, Fukuhara K, Miyazaki A, and Horiuchi S. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipopro-teins. Biochem Biophys Res Commun 280: 1183-1188, 2001.
367. Zieman SJ, Melenovsky V, and Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arter-ioscler Thromb Vasc Biol 25: 932-943, 2005.
368. Zoltowska M, Delvin E, Ziv E, Peretti N, Chartre M, and Levy E. Impact of in vivo glycation of LDL on platelet aggregation and monocyte chemotaxis in diabetic Psamm-omys obesus. Lipids 39: 81-85, 2004